ResMed Inc.RMD
NYSE • Healthcare
$229.12
P/E
22.65
PEG
0.01
FCF Yield
—
Rev Growth YoY
+957.0% YoY
Gross Margin
6085.0%
Health Score
7/10
D/E Ratio
0.11
Confidence
LOW
Business Snapshot
ResMed is a global medical device and software company specialising in cloud-connected devices for sleep apnea, COPD, and other respiratory conditions, alongside SaaS solutions for out-of-hospital care management. It operates primarily in the U.S., Europe, and Asia-Pacific, competing in the large and growing respiratory health and digital health markets. Based on the current price of $229.12 and the data available, ResMed is a well-established large-cap healthcare name trading on the NYSE.
Financial Health
**Score: 7/10** ResMed's balance sheet is notably conservative, with a debt-to-equity ratio of just 0.11x, indicating minimal financial leverage and low refinancing risk. The current ratio of 3.44x suggests strong short-term liquidity, meaning the company holds more than three dollars in current assets for every dollar of near-term liabilities...
Risk Assessment
- **DATA INTEGRITY: Revenue growth of 957% YoY and gross margin of 6,085% are statistically implausible for an established company and strongly suggest data normalisation errors or base-period distortions, rendering these metrics unreliable for investment decisions.** - **CASH FLOW VISIBILITY: Free cash flow is listed as N/A, making it impossible to assess earnings quality or the sustainability of capital allocation.** - **TECHNICALS: A confirmed death cross (50-day MA crossing below 200-day MA) is in place, a bearish medium-term momentum signal, with current price trading below both moving averages.** - **PRICE POSITION: At $229.12, RMD sits 22% below its 52-week high of $293.81, indicating meaningful price deterioration from recent peaks.** - **EARNINGS CONSISTENCY: RMD beat estimates in only 2 of the last 4 quarters, suggesting forecasting uncertainty and limited near-term earnings predictability.** ---...